Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H26N2O2.ClH |
Molecular Weight | 410.936 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC(=O)C1=CC2=C(NC=C2CCCCN3CCC(=CC3)C4=CC=CC=C4)C=C1
InChI
InChIKey=LRJUHOBITQUXIO-UHFFFAOYSA-N
InChI=1S/C24H26N2O2.ClH/c27-24(28)20-9-10-23-22(16-20)21(17-25-23)8-4-5-13-26-14-11-19(12-15-26)18-6-2-1-3-7-18;/h1-3,6-7,9-11,16-17,25H,4-5,8,12-15H2,(H,27,28);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C24H26N2O2 |
Molecular Weight | 374.4754 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Carmoxirole is a dopamine D2 receptor agonist with limited central activity that modulates sympathetic activation and subsequently reduces pre-load and afterload in animals. It was shown, that carmoxirole induced beneficial effects on hemodynamic and neurohumoral parameters in heart failure. In addition, experimental evidence showed that carmoxirole lowered blood pressure in various models of hypertension mainly or exclusively through inhibition of noradrenaline release from sympathetic nerve endings. That effect of carmoxirole was mediated by presynaptic dopamine receptors with the characteristic that release inhibition was restricted to low rates of sympathetic nerve discharge.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1356782
Curator's Comment: Known to be CNS penetrant in animal. Human data not available
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1682817 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9825185
Carmoxirole (0.25-1.00 mg) was administered on 2 consecutive days, and hemodynamic and neurohormonal measurements were carried out.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7757314
10 microM carmoxirole inhibited the adrenaline induced aggregation velocity by 10%: Increasing the carmoxirole concentration caused dose dependent inhibition which was complete at 1 mM. Carmoxirole itself caused a weak aggregating effect on human platelets in vitro.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:53:50 GMT 2023
by
admin
on
Fri Dec 15 15:53:50 GMT 2023
|
Record UNII |
77K7K97CBS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
115092-85-8
Created by
admin on Fri Dec 15 15:53:50 GMT 2023 , Edited by admin on Fri Dec 15 15:53:50 GMT 2023
|
PRIMARY | |||
|
m626
Created by
admin on Fri Dec 15 15:53:50 GMT 2023 , Edited by admin on Fri Dec 15 15:53:50 GMT 2023
|
PRIMARY | Merck Index | ||
|
9822866
Created by
admin on Fri Dec 15 15:53:50 GMT 2023 , Edited by admin on Fri Dec 15 15:53:50 GMT 2023
|
PRIMARY | |||
|
77K7K97CBS
Created by
admin on Fri Dec 15 15:53:50 GMT 2023 , Edited by admin on Fri Dec 15 15:53:50 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |